Related Experiment Video

Updated: Jun 30, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Association of MMP-3 5A/6A gene polymorphism with susceptibility to carotid atherosclerosis

Tamara Djurić¹, Maja Zivković, Djordje Radak

¹VINCA Institute of Nuclear Sciences, Laboratory for Radiobiology and Molecular Genetics, P.O. Box 522, 11001 Belgrade, Serbia. tamariska@vin.bg.ac.yu

Clinical Biochemistry

|September 20, 2008

Abstract

Objectives:

Stromelysin-1 (MMP-3) as a key member of metalloproteinase family could have an important role in atherogenesis. The 5A/6A polymorphism in the promoter of MMP-3 gene affects the level of MMP-3 gene expression. We assessed whether the MMP-3 promoter low- and high-activity genotypes are related to susceptibility for carotid atherosclerosis (CA) in Serbian population.

Design And Methods:

The study group of case-control design consisted of 515 participants. The 265 patients with ultrasonographic evidence of carotid plaque presence were recruited for the study. The 5A/6A polymorphism was typed by RFLP-PCR.

Results:

There was significantly higher prevalence of genotypes containing 6A allele in the patients with CA compared to controls (p<0.05). The model of inheritance with the dominant effect of 6A allele gave elevated and significant OR for carotid atherosclerosis (adjusted OR 2.35, CI=1.0-5.5, p=0.048).

Conclusions:

Subjects carrying genotypes with 6A allele had significantly higher susceptibility to carotid atherosclerosis.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Articles linked to this work by shared authors, journal, and citation graph.

DNA donation decisions, uncertainty, and perceived learning in a Serbian survey on multiple sclerosis genetics.

Patient education and counseling·2026

Limited effect of PCR ramp rate on qPCR Ct values: an exploratory study.

Molecular biology reports·2026

Spaceflight human optimization and performance: positioning astronauts in an operational framework to promote health, fitness, and mission readiness.

Frontiers in physiology·2026

Association Between Multiple Sclerosis Severity and Functional Variants in Key Antioxidant Defense and Ferroptosis-Related Genes.

Biology·2026

Evaluating the impact of mission architecture on crew dynamics in space exploration.

NPJ microgravity·2026

Circulating EV miRNA Cargo in Glioblastoma Patients Is Associated with Distinct Gene Expression Signatures in Peripheral Immune Cells, Suggesting an Early, Compartment-Specific Immune Priming State.

Biomedicines·2026

See all related articles